286 related articles for article (PubMed ID: 33436328)
1. Investigating the association between the urinary microbiome and bladder cancer: An exploratory study.
Hussein AA; Elsayed AS; Durrani M; Jing Z; Iqbal U; Gomez EC; Singh PK; Liu S; Smith G; Tang L; Guru KA
Urol Oncol; 2021 Jun; 39(6):370.e9-370.e19. PubMed ID: 33436328
[TBL] [Abstract][Full Text] [Related]
2. The bladder microbiota is not significantly altered by intravesical BCG therapy.
Heidrich V; Mariotti ACH; Inoue LT; Coser EM; Dos Santos EX; Dos Santos HDB; Asprino PF; Bettoni F; Costa GAP; Bastos DA; Jardim DL; Arap MA; Camargo AA
Urol Oncol; 2024 Jan; 42(1):22.e13-22.e21. PubMed ID: 38030469
[TBL] [Abstract][Full Text] [Related]
3. Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.
James C; Gomez K; Desai S; Patel HD; Rac G; Doshi CP; Dornbier R; Bajic P; Halverson T; Gupta GN; Quek ML; Gorbonos A; Flanigan R; Wolfe AJ
Front Cell Infect Microbiol; 2023; 13():1125809. PubMed ID: 37091677
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
5. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
6. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
7. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
8. Does the urinary microbiome profile change after treatment of bladder cancer?
Hussein AA; Bhat TA; Jing Z; Gomez EC; Wasay MA; Singh PK; Liu S; Smith G; Guru KA
World J Urol; 2023 Dec; 41(12):3593-3598. PubMed ID: 37796319
[TBL] [Abstract][Full Text] [Related]
9. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
[TBL] [Abstract][Full Text] [Related]
10. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
11. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
12. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages.
Khanna A; Yerram N; Zhu H; Kim S; Abouassaly R
Urology; 2019 Feb; 124():120-126. PubMed ID: 30219556
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
[TBL] [Abstract][Full Text] [Related]
15. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center.
Bree KK; Hensley PJ; Brooks N; Matulay J; Nogueras-Gonzalez GM; Navai N; Dinney CP; Kamat AM
World J Urol; 2021 Nov; 39(11):4143-4149. PubMed ID: 34117914
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.
Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
18. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.
Brooks NA; Kokorovic A; Xiao L; Matulay JT; Li R; Ranasinghe WKB; Nagaraju S; Shen Y; Gao J; Navai N; Dinney CPN; Grossman HB; Kamat AM
BJU Int; 2021 Jul; 128(1):65-71. PubMed ID: 33210440
[TBL] [Abstract][Full Text] [Related]
19. Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.
Daniels MJ; Barry E; Schoenberg M; Lamm DL; Bivalacqua TJ; Sankin A; Kates M
Urol Oncol; 2020 Jan; 38(1):5.e9-5.e16. PubMed ID: 31255541
[TBL] [Abstract][Full Text] [Related]
20. Smoke load prognostic impact on bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer.
Andrade DL; Moretti TBC; Neto WA; Benedetti J; Reis LO
Int Urol Nephrol; 2020 Aug; 52(8):1471-1476. PubMed ID: 32157620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
